Treatment of HYpertension: Morning Versus Evening (THYME)
Primary Purpose
Essential Hypertension
Status
Unknown status
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Enalapril/hydrochlorothiazide
Placebo
Sponsored by
About this trial
This is an interventional treatment trial for Essential Hypertension focused on measuring Dipper, Non-dipper, Chronopharmacology
Eligibility Criteria
Inclusion Criteria:
- Essential hypertension
- Stable blood pressure on treatment with Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Blocker (ARB) and hydrochlorothiazide
- Age between 18 and 85 years
- WHO performance status 0-1
- Available for a time period of 15 weeks
- Written informed consent
- Dippers: Nocturnal blood pressure fall of 10-20% of daytime values.20
- Non-dippers: -Nocturnal blood pressure fall of <10% of daytime values
Exclusion Criteria:
- secondary cause of hypertension
- use of ARB because of intolerability (e.g. dry cough) of ACEI
- nocturnal blood pressure fall of >20% or rise
- renal insufficiency (GFR<60 ml/min)
- shift work
- pregnancy or wish to get pregnant
- use of other antihypertensive medication than ACEI, ARB, hydrochlorothiazide or a calcium channel blocker
- use of sleeping medication
Sites / Locations
- Erasmus MC
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Enalapril/hydrochlorothiazide
Placebo
Arm Description
This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
Outcomes
Primary Outcome Measures
Average nocturnal blood pressure, percentage dipping and nadir of nocturnal blood pressure
At the end of each treatment period of six weeks, a 24 hour ambulatory blood pressure measurement will be performed
Secondary Outcome Measures
Percentage of nocturnal diastolic blood pressure measurements below 65 mm hg
One safety issue on evening administration of antihypertensive treatment is that blood pressure might get too low. We will assess this especially in the dippers.
Urine: Sodium, potassium, protein, melatonin, creatinin
Excretion of sodium, potassium, protein and melatonin depend on the circadian clock. Therefore, differences between morning and evening administration of antihypertensive medication are tested
Plasma: enalapril, cortisol, melatonin, aldosterone, ACE activity, gene expression of clock genes
Full Information
NCT ID
NCT02214498
First Posted
August 8, 2014
Last Updated
August 13, 2014
Sponsor
Erasmus Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
1. Study Identification
Unique Protocol Identification Number
NCT02214498
Brief Title
Treatment of HYpertension: Morning Versus Evening
Acronym
THYME
Official Title
Treatment of HYpertension: Morning Versus Evening
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Unknown status
Study Start Date
May 2015 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
May 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Erasmus Medical Center
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Rationale:
The nocturnal blood pressure mean is an independent and stronger predictor of cardiovascular disease (CVD) risk than either daytime office, awake or 24hour mean blood pressure. In general, when nocturnal blood pressure does not decline CVD risk is higher, usually referred to as "dippers" versus "non-dippers". Evening administration of treatment might lower nocturnal blood pressure more effectively than morning administration, which is most commonly advised.
The main hypothesis of this study is that evening administration of antihypertensive medication might resume the dipping pattern in non-dippers and as a consequence might reduce CVD risk more than morning administration.
Primary objective (in short):
-to prove that evening administration of enalapril/hydrochlorothiazide in non-dippers can resume a dipping blood pressure pattern in non-dippers
Study design: A double-blind placebo-controlled cross-over study Each person will use for one period of six weeks enalapril/hydrochlorothiazide in the morning and placebo in the evening, and one period of six weeks the other way around
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Essential Hypertension
Keywords
Dipper, Non-dipper, Chronopharmacology
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Enalapril/hydrochlorothiazide
Arm Type
Active Comparator
Arm Description
This arm will start with six weeks of administration of enalapril/hydrochlorothiazide in the evening and placebo in the morning, followed by six weeks of active treatment in the morning and placebo in the evening
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
This arm will start with six weeks of morning administration of enalapril/hydrochlorothiazide in the morning and placebo in the evening, followed by six weeks of placebo in the morning and active treatment in the evening
Intervention Type
Drug
Intervention Name(s)
Enalapril/hydrochlorothiazide
Other Intervention Name(s)
To be determined
Intervention Description
The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Average nocturnal blood pressure, percentage dipping and nadir of nocturnal blood pressure
Description
At the end of each treatment period of six weeks, a 24 hour ambulatory blood pressure measurement will be performed
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Percentage of nocturnal diastolic blood pressure measurements below 65 mm hg
Description
One safety issue on evening administration of antihypertensive treatment is that blood pressure might get too low. We will assess this especially in the dippers.
Time Frame
24 hours
Title
Urine: Sodium, potassium, protein, melatonin, creatinin
Description
Excretion of sodium, potassium, protein and melatonin depend on the circadian clock. Therefore, differences between morning and evening administration of antihypertensive medication are tested
Time Frame
Two times within 24 hours at the end of six weeks of treatment according to one of the two regimes
Title
Plasma: enalapril, cortisol, melatonin, aldosterone, ACE activity, gene expression of clock genes
Time Frame
Moring of 24 hour blood pressure measurement after six weeks of treatment according to a certain regime
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Essential hypertension
Stable blood pressure on treatment with Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin II Receptor Blocker (ARB) and hydrochlorothiazide
Age between 18 and 85 years
WHO performance status 0-1
Available for a time period of 15 weeks
Written informed consent
Dippers: Nocturnal blood pressure fall of 10-20% of daytime values.20
Non-dippers: -Nocturnal blood pressure fall of <10% of daytime values
Exclusion Criteria:
secondary cause of hypertension
use of ARB because of intolerability (e.g. dry cough) of ACEI
nocturnal blood pressure fall of >20% or rise
renal insufficiency (GFR<60 ml/min)
shift work
pregnancy or wish to get pregnant
use of other antihypertensive medication than ACEI, ARB, hydrochlorothiazide or a calcium channel blocker
use of sleeping medication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jorie Versmissen, MD, PhD
Email
j.versmissen@erasmusmc.nl
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jorie Versmissen, MD, PhD
Organizational Affiliation
Erasmus Medical Center
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Teun Van Gelder, Prof
Organizational Affiliation
Erasmus Medical Center
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Eric Sijbrands, Prof
Organizational Affiliation
Erasmus Medical Center
Official's Role
Study Chair
Facility Information:
Facility Name
Erasmus MC
City
Rotterdam
Country
Netherlands
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jorie Versmissen, MD, PhD
Email
j.versmissen@erasmusmc.nl
First Name & Middle Initial & Last Name & Degree
Jorie Versmissen, MD, PhD
12. IPD Sharing Statement
Learn more about this trial
Treatment of HYpertension: Morning Versus Evening
We'll reach out to this number within 24 hrs